Clinical Research Trial Resources

 

Clinical Trials - a service of the US NIH
ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.

 

The Center for Information & Study on Clinical Research Participation (CISCRP)
CISCRP (Center for Information and Study on Clinical Research Participation) is a first-of-its-kind nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media, and policy makers about clinical research and the role each party plays in the process.
Learn more at www.ciscrp.org

 

Coalition for Clinical Trials Awareness (CCTA)
The mission of the Coalition for Clinical Trials Awareness is to advocate for the creation of a federally sponsored public awareness campaign to increase the public’s understanding of the benefits of clinical trials. 
Learn more at www.cctawareness.org

 

United States National Library of Medicine, National Institutes of Health 
The National Library of Medicine (NLM), on the campus of the National Institutes of Health in Bethesda, Maryland, has been a center of information innovation since its founding in 1836. The world’s largest biomedical library, NLM maintains and makes available a vast print collection and produces electronic information resources on a wide range of topics that are searched billions of times each year by millions of people around the globe. It also supports and conducts research, development, and training in biomedical informatics and health information technology. In addition, the Library coordinates a 6,500-member Network of the NLM that promotes and provides access to health information in communities across the United States. 
Learn more at www.nlm.nih.gov

 

Office of Research on Women's Health, Office of the NIH Director, National Institutes of Health/DHHS
ORWH is the first Public Health Service office dedicated specifically to promote women's health research within and beyond the NIH scientific community. Women's health research is an essential part of the NIH research agenda. The field includes the study of health throughout the lifespan and across the spectrum of scientific investigations. Learn more at www.orwh.od.nih.gov

 

​

 

Current Lupus Studies

 

NEX-T Study

BMS is conducting a clinical trial to evaluate the tolerability, preliminary efficacy, and pharmacokinetics  of a study drug in adult participants, ages 18-75 years old, with severe refractory Systemic Lupus Erythematosus (SLE).  This is a phase 1 study with 11 study sites in the United States.  The study treatment period will last about 28 days, with follow up approximately every 28 days for 6 months, then quarterly follow up for about 2 years.

Click here to learn more about the NEXT-T Study 

​

RestoreD Study
Alexion, AstraZeneca Rare Disease is conducting a phase 2 clinical trial called RestoreD, evaluating an oral investigational medication for adults between 18-75 years of age who have been diagnosed with lupus nephritis (LN) or Immunoglobulin A nephropathy (IgAN). To learn more and see if you may qualify to participate, talk to your doctor and visit www.RestoreDStudy.com 
 

RESET-SLE Study

Cabaletta Bio is conducting a Phase 1/2 clinical trial to evaluate the safety, tolerability and effectiveness of an investigational therapy, including whether this therapy leads to an improvement in lupus symptoms while allowing participants to stop other lupus-related medications. The study is seeking participants aged 18-65 with Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN), with disease activity despite prior or current treatments, and is currently open for enrollment at centers in the United States.

Click here to learn more about the RESET-SLE study

ELEVATE Study
DxTerity Diagnostics, a Los Angeles based genomics company, is sponsoring an observational research study that uses participant’s health information and a few drops of blood to better understand what it means to live with and manage lupus. They are looking to find a better, easier, and more convenient way for people living with lupus to track and manage their disease from home.
Learn more at www.TheElevateStudy.com

​

POETYK SLE-1 and SLE-2 Study

BMS is conducting a clinical trial to evaluate the effectiveness, safety and tolerability of a study drug in adult participants, ages 18-75 years old, with active Systemic Lupus Erythematosus (SLE). This is a phase 3 study currently being conducted in 16 countries including the United States.  The study will last over 1 year, about 60 weeks.  Learn more at Learn More About SLE Studies

​

RC18G001 Study
RemeGen is conducting a global Phase 3 clinical study to evaluate the safety and efficacy of an investigational medication to treat adults 18-70 years old with systemic lupus erythematosus (SLE) who meet eligibility criteria. To be eligible for the study, patients should have moderate or severe SLE despite receiving standard of care therapies. The study is seeking participants at multiple clinical trial sites in the United States, Europe, Asia, Australia, and South America. This medication is currently approved and available as a prescription to patients in China.  Click here to learn more about the RC18G001 Study

PALIZADE Study

Kezar Life Sciences is evaluating an investigational medication in a clinical research study to determine whether it can help people living with lupus nephritis (LN). They are currently looking for participants with lupus nephritis to be enrolled into the Phase 2b portion of the study at multiple clinical trial sites in the United States.
Learn more at www.palizadetrial.com 

​

IM026-024 SLE Study

BMS is conducting a clinical trial to evaluate the effectiveness, safety and tolerability of a study drug in participants with active Systemic Lupus Erythematosus (SLE). This is a phase 2 study currently being conducted in 17 countries including the United States. The study will last over 1 year, about 57 weeks.
Click here to learn more about the IM026-024 study

JASMINE Study

Janssen is sponsoring a global phase 2 study evaluating the safety and effectiveness of an investigational medication in people with systemic lupus erythematosus (SLE). The study is seeking participants aged 18-65 diagnosed with systemic lupus erythematosus (SLE) 6 months ago or more.

Learn more at https://bit.ly/JasmineSLEStudy

SANCTUARY
Alexion, AstraZeneca Rare Disease is conducting a Phase 2 clinical trial to evaluate the safety and efficacy (effectiveness against disease) of the study medication in participants with lupus nephritis (LN) or immunoglobulin A nephropathy (IgAN), a rare chronic kidney disease. To learn more and see if you may qualify to participate, talk to your doctor, and visit www.sanctuarystudy.com

OPUS Study

Idorsia Pharmaceuticals is conducting two global Phase 3 clinical studies to evaluate the safety and efficacy of an investigational medication compared with placebo in adult participants with moderate to severe SLE in 25 countries. Participants who complete 12 months of treatment will be offered the opportunity to enroll in an open-label study, during which they will receive the study drug for approximately 1.5 years.

Learn more at Link

M011-132 DLE/SCLE Study
BMS is conducting a clinical trial to assess the safety, efficacy and tolerability of a study drug compared with
placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE).
This is a phase 2 study currently being conducted in 9 countries including the United States. The study will
last over 1 year, about 60 weeks.

Click here to learn more about IM011-132

 

TOPAZ Study

Biogen's TOPAZ Study is evaluating the safety and potential efficacy of an investigational medication in people with active systemic lupus erythematosus (SLE) who are still taking their current SLE non-biologic therapy. The TOPAZ Studies will last for a year and a half and include approximately 22 visits to the study site and are being conducted in over 25 countries. 
Learn more at www.topazlupusstudy.com

​

EQUALISE Study
Equillium, Inc. is evaluating the safety and tolerability of an investigational medicine in a phase 1b clinical research study in patients with lupus and lupus nephritis. The study will have two cohorts studied over three defined periods – screening, treatment, and follow-up. The treatment period for patients with systemic lupus erythematosus in Type A Cohort was 4 weeks in duration and is now complete. Treatment for patients with active proliferative lupus nephritis in Type B Cohort is 24 weeks in duration and is also complete with topline data expected early in 2024. 
Learn more at  https://bit.ly/3qLN7g5

​

       

          Current List of Lupus Research Trials in Boston, MA area.

 

          Current list of Lupus Research Trials in Chicago, IL area.
 

Current list of Lupus Research Trials in Detroit, MI area.

 

 

Learn About Clinical Trial Opportunities 

To learn about lupus clinical research trial opportunities go to www.clinicaltrials.gov

1. Type lupus in the search box and click on the search button. 

2. Then click on the On Map tab at the top. 

3. Click on the Geographic Area, Country or State you are interested in and the studies for that area will be listed.

4. Click on a specific study for details about the trial's purpose, study eligibility, inclusion and exclusion criteria, locations, and contact information. 

The Lupus and Allied Diseases Association, Inc., would like to thank Kathleen Arntsen for her efforts in developing the Hope is on the Horizon program and resource material originally developed in 2004 and copyrighted in 2007.